InvestorsHub Logo
Followers 20
Posts 2687
Boards Moderated 1
Alias Born 12/03/2020

Re: C-20 post# 141428

Tuesday, 01/19/2021 9:52:35 AM

Tuesday, January 19, 2021 9:52:35 AM

Post# of 233151
The fact that Cytodyn's DSMC requested a new, unplanned, interim review at 75% for (I quote the CEO, Oct. 20th conference call) "perform a sample size reassessment" speaks to the contrary. Most investors have missed this gem, it was burried ini the middle of a long conf call. These few words means they were trying to mitigate the risk that the trial's 390 patient would not be the right number to demonstrate an hypothetical Leronlimab effect. Writing is on the wall.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News